Private company

Imago BioSciences, Inc.

American pharmaceutical preparations company, incorporated in Delaware1

In its 2022 annual report the company says: “We are a clinical-stage biopharmaceutical company discovering and developing small molecule product candidates that target lysine-specific demethylase-1, or LSD1, an enzyme that plays a central role in the production of blood cells in the bone marrow. We are focused on improving the quality of life of patients with cancer and bone marrow diseases in addition to prolonging their lives. Our lead product candidate is bomedemstat for the treatment of certain myeloproliferative neoplasms, or MPNs, a family of related, chronic cancers of the bone marrow.”42 It is headquartered in Redwood City, California.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersRedwood City, California1
  • Incorporated inDE2
  • Business address303 Twin Dolphin Drive, 6Th Floor, Redwood City, Ca 940652
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income3-$42.5M in 2021+135% since 2020
-$60.0M-$40.0M-$20.0M02020: -$18.1M-$18.1M20202021: -$42.5M-$42.5M2021+135%
Net income3-$42.3M in 2021+137% since 2020
-$60.0M-$40.0M-$20.0M02020: -$17.8M-$17.8M20202021: -$42.3M-$42.3M2021+137%
Fiscal year2019202020212022
Research and development$14.9M3$32.3M3
Operating expenses$42.5M3
Operating income-$18.1M3-$42.5M3
Income before tax-$42.3M3
Income tax$3.0K3$2.0K3
Net income-$17.8M3-$42.3M3

Compare Imago BioSciences, Inc. with another company

Corporate structure

Imago BioSciences, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Imago BioSciences, Inc.

  • CITADEL ADVISORS LLC Filed SC 13G/A on Imago BioSciences, Inc., latest Feb 14, 2023 (2 filings since Feb 14, 2022)
  • Farallon Capital Partners, L.P. Filed SC 13G/A on Imago BioSciences, Inc., latest Feb 1, 2023
  • Clarus Lifesciences III, L.P. Filed SC 13D/A on Imago BioSciences, Inc., latest Jan 12, 2023 (2 filings since Apr 1, 2022)
  • FMR LLC Filed SC 13G/A on Imago BioSciences, Inc., latest Dec 12, 2022 (3 filings since Feb 9, 2022)
  • Frazier Healthcare VII, L.P. Filed SC 13D/A on Imago BioSciences, Inc., latest Nov 14, 2022
  • Omega Fund VI, L.P. Filed SC 13G on Imago BioSciences, Inc., latest Feb 14, 2022
  • PRICE T ROWE ASSOCIATES INC /MD/ Filed SC 13G on Imago BioSciences, Inc., latest Feb 14, 2022
  • FARALLON CAPITAL MANAGEMENT, L.L.C. Filed SC 13G/A on Imago BioSciences, Inc., latest Feb 3, 2022
  • Imago BioSciences, Inc. Redwood City, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Imago BioSciences, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$2.0K3 Dec 31, 2021$8.0K3 Dec 31, 2020−75.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$11.2M3 Dec 31, 2021$19.3M3 Dec 31, 2020−41.7%
Marketable securities, current$206.2M3 Dec 31, 2021$57.4M3 Dec 31, 2020+259.4%
Debt securities available for sale$216.1M3 Dec 31, 2021$95.0M3 Dec 31, 2020+127.4%
Long-term investments$19.7M3 Dec 31, 2020

Leadership

Who has led Imago BioSciences, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Hugh Rienhoff Jr.2021–2023

Chief financial officer

  1. Matthew Plunkett2021
  2. Laura G. Eichorn2022–2023

Chief operating officer

  1. Laura G. Eichorn2021
2025
Board members and other officers (11)

Timeline

  1. Jan 11, 20238-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights20
  2. Dec 12, 20228-K Regulation FD disclosure21
  3. Nov 21, 20228-K Entered a material agreement; Other events22
  4. Nov 9, 20228-K Results of operations23
  5. Sep 1, 20228-K Executive or director change24
  6. Aug 18, 20228-K Other events25
  7. Aug 12, 20228-K Results of operations26
  8. Jun 13, 20228-K Regulation FD disclosure27
  9. Jun 10, 20228-K Regulation FD disclosure28
  10. Jun 6, 20228-K Shareholder vote29
  11. May 12, 20228-K Regulation FD disclosure30
  12. May 12, 20228-K Results of operations31
  13. Jul 15, 2021New chief executive Hugh Rienhoff Jr. becomes CEO6

Calendar

When it reported results

  1. Nov 9, 2022Reported quarterly or annual results23
  2. Aug 12, 2022Reported quarterly or annual results26
  3. May 12, 2022Reported quarterly or annual results31
  4. Mar 24, 2022Reported quarterly or annual results32
  5. Nov 10, 2021Reported quarterly or annual results33

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

124 filings to the SEC since October 2021: 1 annual reports, 4 quarterly reports, 20 major events, 69 insider forms, 12 large holders, 18 other. The latest 20:

  1. Feb 14, 2023SC 13G/A EDGAR
  2. Feb 1, 2023SC 13G/A AMENDMENT #2 EDGAR
  3. Jan 23, 202315-12G EDGAR
  4. Jan 13, 2023EFFECT EDGAR
  5. Jan 12, 2023SC 13D/A EDGAR
  6. Jan 11, 2023S-8 POS EDGAR
  7. Jan 11, 2023S-8 POS EDGAR
  8. Jan 11, 2023POS AM EDGAR
  9. Jan 11, 20238-K EDGAR
  10. Jan 11, 2023SC 14D9/A EDGAR
  11. Jan 11, 20234 FORM 4 SUBMISSION EDGAR
  12. Jan 11, 20234 FORM 4 SUBMISSION EDGAR
  13. Jan 11, 20234 FORM 4 SUBMISSION EDGAR
  14. Jan 11, 20234 FORM 4 SUBMISSION EDGAR
  15. Jan 11, 20234 FORM 4 SUBMISSION EDGAR
  16. Jan 11, 20234 FORM 4 SUBMISSION EDGAR
  17. Jan 11, 20234 FORM 4 SUBMISSION EDGAR
  18. Jan 11, 20234 FORM 4 SUBMISSION EDGAR
  19. Jan 11, 20234 FORM 4 SUBMISSION EDGAR
  20. Jan 11, 20234 FORM 4 SUBMISSION EDGAR

The 124 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

32 open-market trades by officers, directors and large owners since October 2021: 0 buys and 32 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 27, 2022Eichorn Laura G.Chief Financial OfficerSale3,100$35.93$111.4KForm 4
Dec 27, 2022Arenberg MichaelSee RemarksSale70,508$35.93$2.5MForm 4
Dec 16, 2022Tapper Amy E.Chief, Technical OperationsSale100,302$35.78$3.6MForm 4
Dec 16, 2022Arenberg MichaelSee RemarksSale47,750$35.78$1.7MForm 4
Dec 16, 2022Rienhoff Hugh JRChief Executive OfficerSale266,784$35.78$9.5MForm 4
Dec 15, 2022Peppe JenniferSee RemarksSale119,422$35.80$4.3MForm 4
Dec 15, 2022Peppe JenniferSee RemarksSale119,422$35.80$4.3MForm 4
Dec 15, 2022Eichorn Laura G.Chief Financial OfficerSale126,714$35.79$4.5MForm 4
Dec 15, 2022Rienhoff Hugh JRChief Executive OfficerSale206,309$35.80$7.4MForm 4
Nov 2, 2022Tapper Amy E.Chief, Technical OperationsSale750$17.90$13.4KForm 4
Nov 2, 2022Eichorn Laura G.Chief Financial OfficerSale553$18.00$10.0KForm 4
Aug 22, 2022Eichorn Laura G.Chief Financial OfficerSale447$18.00$8.0KForm 4
Aug 17, 2022Eichorn Laura G.Chief Financial OfficerSale373$19.50$7.3KForm 4
Aug 16, 2022Eichorn Laura G.Chief Financial OfficerSale533$19.50$10.4KForm 4
Aug 16, 2022Peppe JenniferSee RemarksSale6,402$19.41$124.3KForm 4
Aug 15, 2022Peppe JenniferSee RemarksSale5,598$19.41$108.7KForm 4
Aug 15, 2022Tapper Amy E.Chief, Technical OperationsSale11,500$19.26$221.5KForm 4
Aug 12, 2022Tapper Amy E.Chief, Technical OperationsSale750$17.90$13.4KForm 4
Jul 20, 2022Eichorn Laura G.Chief Financial OfficerSale1,000$18.00$18.0KForm 4
Jul 20, 2022Tapper Amy E.Chief, Technical OperationsSale750$17.90$13.4KForm 4

All 32 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Imago BioSciences, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARImago BioSciences, Inc.1
  • CIK0001623715
  • Employer ID (EIN)45-49158101
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address303 Twin Dolphin Drive, 6Th Floor, Redwood City, CA 940651
  • Phone(415) 529-50551
  • Shares outstanding33,822,201 as of Nov 2, 20225
  • Public float$0 as of Jun 30, 20213
  • On EDGAR sinceDec 11, 20141
  • Filings183 in all: 4 (74), 8-K (24), 3 (16), SC 13G/A (8), SC 13G (6), 10-Q (5), CORRESP (4), D (3)1
    All 38 form types

    EFFECT (3), SC 13D/A (3), SC 14D9/A (3), UPLOAD (3), S-1/A (2), S-8 (2), S-8 POS (2), SC 13D (2), SC TO-T/A (2), 10-K (1), 15-12G (1), 25-NSE (1), 424B4 (1), 424B5 (1), 8-A12B (1), CERT (1), D/A (1), DEF 14A (1), DEFA14A (1), DRS (1), DRS/A (1), DRSLTR (1), POS AM (1), S-1 (1), S-1MEF (1), S-3 (1), SC 14D9 (1), SC TO-C (1), SC TO-T (1), SC14D9C (1)

  • Latest filingsAnnual report (10-K) Mar 24, 2022
    Quarterly report (10-Q) Nov 9, 2022
    Proxy statement (DEF 14A) Apr 19, 2022
    Latest 8-K (8-K) Jan 11, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
    SEC EDGAROther events
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42